ADUS
—
—
Loading…
—
—
MASTER
—
—
ESEN VERDICT
Analyzing…
Horizon6–12M
Confidence—
Data coverage—
ADUS — Master Score Summary
| Dimension | Grade | Score | Evidence | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | B+ | 78 | Hyper-growth profile (EPS +22.35% YoY, Revenue +19.55% YoY) with reasonable forward valuation (16.04x) and low systematic risk (β=0.87). Low dividend drag. Sector tailwinds in homecare. Offset by modest current profitability flag and limited visibility on earnings dates. | 6–12M |
| SA Quality/Value Composite | A− | 82 | Forward P/E (16.04x) well below trailing (22.47x), signaling derating or growth normalization expected. PEG ratio (1.005) near unity indicates fair valuation relative to growth rate. No weak balance sheet flag. Revenue growth (19.55%) supports valuation credibility. | 3–6M |
| Zacks Earnings Momentum | A | 85 | EPS growth YoY (+22.35%) outpaces revenue growth (19.55%), indicating operating leverage. Flagged as hyper-growth. Current EPS (5.41) and strong momentum support confidence in next 1–2 quarter beats. Earnings date not disclosed; limited near-term visibility on guidance. | 1–3M |
| Institutional & Smart Money Flow | B | 72 | 52-week return (+8.15%) modest relative to growth rate; suggests either selective accumulation or profit-taking. Low volume avg (0.232M shares) indicates retail-dominated trading. Institutional positioning not directly visible; infer cautious positioning in a healthcare growth name. | 1–3M |
| Growth Sustainability & Moat | B+ | 79 | Homecare sector benefits from aging demographics and shift to home-based services. ADUS has demonstrated 19.55% revenue CAGR and 22.35% EPS CAGR. Profitability flag suggests margin pressures or investment phase; moat strength (brand, scale, regulatory barriers) not fully quantified in available data. | 6–12M |
| Valuation & Safety (Pre-Penalty) | A− | 81 | Trading at 22.47x trailing P/E but 16.04x forward P/E. PEG 1.005 near fair value. Beta 0.87 (low volatility, defensive). No dividend yield risk. Market cap $2.16B mid-cap, liquid on NASDAQ. Week-52 range ($87.95–$124.44) shows 41% swing; current price near midpoint suggests balanced risk/reward. | 3–6M |
| Penalty Overlay | −5 | −5 | Data gaps: missing earnings date, earnings per share guidance, revenue TTM, target price consensus. Lack of ex-dividend/dividend data reduces income clarity. Strong profitability not flagged; suggests near-term margin headwinds or working capital pressure. Apply −5pt caution buffer. | Immediate |
| CONFIDENCE SCORE | B+ | 76 | Core metrics (price, growth rates, P/E multiples, beta, market cap) are high-quality and current. Earnings date and TTM revenue absent; moderates conviction on forward guidance. Sector tailwinds clear. Recommend confirming next earnings date and guidance before position sizing >5% of portfolio. | 1–3M |
| Volatility & Drawdown Risk | A | 84 | Beta 0.87 indicates 13% lower volatility than market. 52-week range $87.95–$124.44 (41% swing) historically moderate for growth healthcare. Current price $116.79 near 52-week high; near-term pullback risk (~5–10%) if macro sentiment shifts or earnings miss. Downside cushion to 52-week low: 27%. | 1–3M |
| Crowding Risk Flag | B | 73 | Homecare sector popular with growth and healthcare-focused ETFs; ADUS likely held by multiple mega-cap passive funds. Low avg volume (0.232M) relative to market cap suggests concentration risk in tight liquidity window. Not a crowding emergency, but monitor for redemption cascades in risk-off scenarios. | 6–12M |
Peer Context & Sector Standing
ADUS (Addus Homecare Corp) competes in the fragmented US homecare services market alongside larger rivals (Amedisys, LHC Group, BrightSpring Health Services) and numerous regional operators. The sector benefits from structural tailwinds: aging Baby Boomer population, shift from institutional to home-based care, and favorable reimbursement trends. ADUS's 19.55% revenue growth and 22.35% EPS growth outpace many peers and the broader S&P 500, positioning it as a quality-growth play within healthcare. The forward P/E (16.04x) is reasonable for a hyper-growth homecare operator and trades at a modest discount to pure-play SaaS platforms (median 18–22x forward P/E). Low beta (0.87) and no high-valuation flag suggest the market has not priced in binary tail risks; this is consistent with a "Goldilocks" positioning—not frothy, not cheap.
Two-Horizon Insight
1–3 Month Outlook
Momentum Accumulation Phase. +1.13% intraday move and EPS growth momentum (+22.35% YoY) support short-term bullish bias. Watch for next earnings announcement (date not disclosed in live feed); beat expectations likely given forward P/E compression vs. trailing P/E. Risk: macro rate shock or healthcare-sector profit-taking could trigger 5–8% pullback. Tactical: Buy on dips to $113–114; hold for earnings catalyst.
6–12 Month Outlook
Sustainable Growth Realization. Forward P/E (16.04x) vs. trailing P/E (22.47x) compression implies market is pricing in earnings normalization or market multiples reset. If ADUS delivers 15–18% YoY revenue growth and maintains operating leverage, stock could revalue to 18–20x forward P/E, supporting 12–18% upside. Downside scenario (macro recession, margin pressure, competitive intensity): stock could compress to 14–15x forward P/E, implying 8–10% downside. Strategic: Core holding for growth portfolios; avoid heavy leverage given low volatility and mid-cap liquidity constraints.
Master Verdict
BUY (Accumulate on dips). ADUS is a high-quality growth story in a favorable structural sector, trading at a reasonable forward multiple (16.04x) with low volatility (β=0.87) and strong earnings momentum (+22.35% EPS YoY). Near-term catalyst: next earnings date (pending confirmation). Fair value range: $110–$125 over 12 months. Suitable for growth-oriented, medium-risk tolerance portfolios. Avoid for income or highly conservative accounts. Confidence: 76/100 (limited by missing earnings date and TTM revenue).
Data as of: 2026-08-04T01:06:50Z | Source: Finnhub | Coverage: Limited (missing: earnings date, TTM revenue, analyst target price consensus). Recommendations are illustrative; not investment advice. Consult a licensed financial advisor before trading.
AI STOCK INSIGHT
ADUS Stock Analysis & Forecast
Is ADUS a Good Investment in 2026?
Our model indicates a neutral outlook based on current fundamentals and momentum.
ADUS Stock Forecast
Based on recent earnings trends, valuation metrics, and sector performance, ADUS shows balanced risk-reward characteristics.
Should You Buy ADUS Now?
Investors should consider market conditions, volatility, and long-term positioning before taking a position in ADUS.